19643 Investors following Dr Reddys Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Dr Reddy's diabetes molecule likely to enter phase-III soon
Dr Reddy's Laboratories Ltd, which has lined up seven new chemical entities in its drug discovery fold, is hopeful of its most promising diabetes molecule DRF-2593 (Balaglitazone) to enter the phase-III clinical trials soon.
The company is currently focussing broadly on metabolic disorders, cardiovascular indications, bacterial infections and cancer segments for its drug discovery research and of the seven NCEs, four are now in clinical development and three in pre-clinical stages. The other two molecules that entered the phase-II clinical trials include DRF-10945 (anti cholesterol) and DRF-1042 (anti-cancer).
According to Dr Suresh Kankanwadi, the strategy of Dr Reddy's is to continue expanding its discovery pipeline with increased focus on creating new discovery platforms in the two key therapeutic segments of cardiovascular and metabolic disorders. The priority of the company is to accelerate the NCEs in the discovery pipeline up to phase-IIa trials and then go in for out-licensing or co-develop
